(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

 

New Delhi, the 26^th July, 2011

 

ORDER

S.O. 1737(E) – In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) and (7) of paragraph 8 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (4) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales Taxes/VAT and local taxes, if any, and in column (5) as equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s. Eli Lilly and Company (I) Pvt. Ltd.

 

TABLE

Sl. No.	Name of the  formulation	Pack Size	Retail Price  without   Excise Duty  Sales Tax /VAT  and Local Tax, if any  (Rs.)	Equivalent MRP* inclusive of all  taxes   (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Monocomponent Insulin  Humalog Kwik Mix 25 Pen    100 IU/ml  Each ml of 25% Insulin Lispro and 75% Insulin Lispro Protamine Suspension contains: 100 IU Insulin Lispro PH. Eur (r-DNA origin) Batch No. A812548D / Qty. 1500 Prefilled Pens	3 ml Prefilled  Kwik Pen	482.33	501.62
2.	Monocomponent Insulin Humalog Kwik Mix 50 Pen  100 IU/ml Each ml of 50% Insulin Lispro and 50% Insulin Lispro Protamine Suspension contains: 100 IU Insulin Lispro PH. Eur (r-DNA origin) Batch no. A812369D / Qty. 30310 Prefilled Pens Batch no. A812369J / Qty. 14845  Prefilled Pens	3 ml Prefilled  Kwik Pen	482.33	501.62
3.	Monocomponent Insulin   Humalog Kwik Pen 100 IU/ml (Insulin Lispro) Each ml of Insulin Lispro contians: 100 IU Insulin Lispro Ph. Eur (r-DNA origin) Batch no. A829407C/ Qty. 30235 Prefilled Pens	3ml Prefilled Kwik Pen	482.33	501.62
4.	Monocomponent Insulin  Humalog Mix 25 100 IU/ml(Insulin Lispro) Each ml contain 25% Insulin Lispro and 75% Insulin Lispro Protamine suspension, 100 IU Insulin Lispro (r-DNA Origin) Batch No. A834666R / Qty. 5000 Cartridge	3ml   Cartridge	357.75	372.06
5.	Monocomponent Insulin  Humalog Mix 50 100IU/ml  (Insulin Lispro) Each ml contain 50% Insulin Lispro and 50% Insulin Lispro Protamine Suspension, 100 IU Insulin Lispro Ph. Eur. (r-DNA Origin) Batch No. A847483A/ Qty. 5000 Cartridge Batch No. A852787A/ Qty. 5000 Cartridge	3ml   Cartridge	357.75	372.06
6.	Monocomponent Insulin  Humalog 100 IU/ml(Insulin Lispro) Each ml contain 100 IU Insulin Lispro Ph. Eur. (r-DNA origin) Batch No. A847484C/ Qty. 5000 Cartridge	3ml Cartridge	357.75	372.06
7.	Monocomponent Insulin  Huminsulin 30/70 – 100 IU/ml (30% Neutral Insulin Solution & 70% Isophane Suspension Human) Anti Diabetc Each ml of 30% Neutral Insulin Solution & 70% Isophane Suspension Human contains: 100 IU Human insulin Ph. Eur. (r-DNA origin) Batch No. A846688C / Qty. 5000 Cartridge Batch No. A846688F / Qty. 114010 Cartridge	3ml Cartridge	202.97	211.09
8.	Monocomponent Insulin  Huminsulin 30/70 – 100 IU/ml (30% Neutral Insulin Solution & 70%Isophane Suspension Human) Anti Diabetc Each ml of 30% Neutral Insulin Solution & 70% Isophane Suspension Human contains: 100 IU Human insulin Ph. Eur. (r-DNA origin) Batch No. HIM772/ Qty. 960 Vials Batch No. HIM773/ Qty. 960 Vials	10ml   Vial	369.34	384.11
9.	Monocomponent Insulin Huminsulin Regular 100 IU/ml Each ml contain 100 IU Human Insulin (r-DNA origin) B.No. A842595A/ Qty. 5000 Cartridges	3ml     Cartridge	202.97	211.09
10.	Monocomponent Insulin  Huminsulin NPH 100 IU/mlEach ml contain 100 IU Human Insulin (r-DNA origin) B.No. A840127A/ Qty. 19605 Cartridges	3ml   Cartridge	202.97	211.09
11.	Monocomponent Human InsulinHuminsulin 30/70 – 40 IU/ml (30% Soluble Insulin & 70% Isophane Insulin) Each ml of 30% Neutral Insulin Solution & 70% Isophane Suspension Human contains: 40 IU Human Insulin Ph. Eur. (r-DNA origin) Batch No. HMX399 / Qty. 960 vials Batch No. HMX400 / Qty. 960 vials Batch No. HMX401 / Qty. 960 vials Batch No. HMX402 / Qty. 960 vials Batch No. HMX403 / Qty. 960 vials Batch No. HMX404 / Qty. 960 vials Batch No. HMX405 / Qty. 960 vials Batch No. HMX406 / Qty. 960 vials Batch No. HMX407 / Qty. 960 vials Batch No. HMX408 / Qty. 960 vials Batch No. HMX408A / Qty. 7312 vials Batch No. HMX408B / Qty. 8266 vials Batch No. HMX409 / Qty. 960 vials Batch No. HMX422A / Qty. 960 vials Batch No. HMX423 / Qty. 960 vials Batch No. HMX424 / Qty. 960 vials	10ml Vial	160.26	166.67”

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

1. The prices fixed are the maximum retail prices in column no. (5) (Inclusive of excise duty, sales tax/VAT and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground there from, unless specifically permitted by the Government/NPPA through an order.
2. The companies / manufacturers may add taxes only if they have paid actually to the Government on the price mentioned in the column (4).  If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
3. For different packing material used or, different drug delivery systems or any other special features/forms claimed, the retail prices, as specified in Column No. 4 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
4. The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
5. These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.
6. These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
7. The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the Essential Commodities Act, 1955.

PN/121/2011/F

F. No. 8(30)/2011/D.P./NPPA-Div.-II

(S. K. BHATT)
Deputy Director

Last Page Updated: 05-02-2019